Zeneca Breaks Records In 1996 As New Products Are Launched
Pretax profits for 1996 were L1.01 billion, passing the L1 billion($1.62 billion) mark for the first time in 1996 at the UK biosciences group Zeneca, up from L878 million in 1995. Earnings per share were 70.6 pence, up 14%. After exceptional items of L36 million, pretax profits were L975 million. Net profits before exceptionals were L669 million.
The group achieved record sales at L5.36 billion, up 9%, with exports exceeding L2 billion for the first time, keeping Zeneca among the UK's leading exporters, noted Sir Sydney Lipworth, group chairman, at the 1996 results presentation in London.
Sir Sydney said that all three of the group's major businesses gave excellent performances, with accelerated development and launches of new products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze